Shots: The approval was based on P-III ADMIRAL assessing gilteritinib (120mg, qd) vs CT in 319 patients with relapsed or refractory AML. The study showed patients had significantly longer overall […]readmore
Tags : R/R Acute Myeloid Leukemia
Shots: On 28 Nov, 2018 Xospata (gilteritinib) received FDA approval as a PO monothx, indicated for r/r FLT3 mutation-positive (FLT3mut+) AML Xospata is accompanied by Xospata Support Solutions offering access […]readmore
Shots: The approval is based on P-I AG120-C-011 (NCT02074839) study results assessing Tibsovo (ivosidenib, 500mg) in 174 patients with r/r AML and IDH1 mutation aged 67 yrs. P-I AG120-C-011 study […]readmore